Immutep (ASX:IMM) announced the initiation of its Phase III clinical trial TACTI-004, which aims to evaluate the effectiveness of its lead immunotherapy candidate, eftilagimod alfa (“efti”), in the first-line treatment of lung cancer metastatic non-small cell (NSCLC).
Efti will be used in combination with Merck’s Keytruda (pembrolizumab) and chemotherapy. This will be compared to the standard treatment of Keytruda with chemotherapy (and a placebo).
The randomized, double-blind study will enroll approximately 750 patients with metastatic NSCLC and will be conducted at more than 150 clinical sites in more than 25 countries.
The trial will measure two primary endpoints: progression-free survival and overall survival.
Marc Voigt, CEO of Immutep, commented: “This…represents a key step toward potentially establishing a new standard of care for patients with metastatic NSCLC. We are confident, based on the strength of the data for eftilagimod alfa, that this can make a significant difference. in the lives of cancer patients, and we look forward to enrolling the first patient in this important study in the first quarter of 2025.”
Shares closed up 1.49% at 34 cents yesterday.
